This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
by Zacks Equity Research
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin (BMRN) Upgraded to Buy: Here's Why
by Zacks Equity Research
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMRN vs. INCY: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMRN vs. INCY: Which Stock Is the Better Value Option?
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
by Zacks Equity Research
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 16.67% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BMRN or MYGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMRN vs. MYGN: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
by Zacks Equity Research
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.